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  Alterations  of  genes  are  known  to  be  critical  for  the 
induction of tumorigenesis, but the mechanism of ovarian 
carcinogenesis  is  little  understood  and  remains  to  be 
elucidated. In this study, we investigated the roles of brca1, 
brca2 and p53 genes in the development of ovarian cancer 
using conditional knockout mice generated by a Cre-loxP 
recombinant system. Following the application of recombinant 
adenovirus  expressing  Cre  in  vitro,  the  proliferation  of 
ovarian  surface  epithelium  (OSE)  was  increased.  For 
instance, a significant increase in cell growth was observed 
in OSE cells in vitro by conditional knockout isolated from 
the  mice  bearing  concurrent  floxed  copies  of  brca1  and 
brca2/p53. However, the proliferative effect of the ovarian 
cells was not observed in concurrent brca1/brca2 or p53 
knockout mice in vivo, indicating that we could not observe 
the direct evidence of the involvement of brca1, brca2, and 
p53  in ovarian  carcinogenesis.  Since  morphological changes 
including  tumor  formation  were  not  observed  in  mice 
bearing floxed copies of concurrent brca1/brca2 or p53, the 
inactivation  of  brca1/2 o r  p53 i s  n o t  s u f f i c i e n t  f o r  t h e  
induction of tumor formation. Taken together, these results 
suggest  that  the  deficiency  of  these  genes  may  not  be 
involved directly in the mechanism of ovarian carcinogenesis.
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tumor suppressor genes
Introduction 
Ovarian cancer is the most lethal cause of cancer-related 
death from gynecological malignancies in Western women 
[1,28]. Approximately 90% of ovarian cancer is believed 
to arise from a single layer of flat to cuboidal cells forming 
the outer layer of ovarian surface epithelium (OSE) 
[1,2,17,26] and OSE has received much attention in the last 
few years. However, the study of the etiology and cellular 
mechanisms of human ovarian cancer was limited because 
there has been no appropriate animal model to explain the 
occurrence of ovarian cancer. Although it has been reported 
that concurrent inactivation of Rb and p53 genes contributes 
to the initiation of ovarian cancer development [12], the 
cause of ovarian carcinogenesis is poorly understood. 
Brca1/2 and p53 are known to play important roles in DNA 
repair and the cell cycle. Recent evidence has shown that 
the mutation of the brca1 gene increases the incidence of 
preneoplastic changes in murine OSE and the inactivation 
of p53 reverses the increase of apoptosis induced by the 
loss of function of brca1 in vivo [9]. This indicates that 
concurrent inactivation of brca1 and p53 pathways may be 
involved in critical changes responsible for the induction 
of ovarian carcinogenesis.
Brca1 and brca2 are the DNA damage repair genes and 
are important in maintaining genomic integrity [7,30,32]. 
The mutation of these genes increases susceptibility to 
ovarian cancer [13] and the inactivation of brca1 induces 
the activation of a number of oncogenes involved in 
tumorigenesis [4,11,35]. The p53 protein is well known as 
a transcriptional factor and functions as a tumor suppressor 
gene. p53 also plays an important role in apoptosis and the 
cell cycle and its mutation is known to be involved in the 
incidence of 50% of human tumors [24]. Furthermore, 
there is accumulating evidence that the loss of brca1 
induces the inactivation of p53, which is involved in 
brca1-associated tumorigenesis [5,10]. Although there 
have been many studies of the role of these genes in ovarian 
carcinogenesis, a definitive elucidation has not been 
achieved because an animal model of ovarian cancer in 292    Ki-Yon Kim et al.
Table 1. The oligo-sequences of the primers and the predicted sizes of PCR products for brca1, brca2, and p53 floxed mice 
mRNA  Gene sequences (5´-3´)  Expected size
brca1 (5´ floxed) Sense TATCACCACTGAATCTCTACC 461-bp
Antisense GACCTCAAACTCTGAGATCCA
brca1 (3´ floxed) Sense  TATTCTTACTTCGTGGCACAT  562-bp
Antisense TCCATAGCATCTCCTTCTAAA
brca2 (5´ floxed) Sense  GGCTGTCTTAGAACTTAGGCT  376-bp
Antisense CTCCACACATACATCATGTGT
brca2 (3´ floxed) Sense  CTCATCATTTGTTGCCTCACTTC  529-bp
Antisense TGTTGGATACAAGGCATGTACAC
p53 Sense  AGCTGAAGACAGAAAAGGGGAGGG  585-bp  (floxed)
 Antisense  ACAGAAAAGGGGAGGGATGAAGTGA  432-bp  (wild)
GAPDH* Sense ACACATTGGGGGTAGGAACA  223-bp
Antisense AACTTTGGCATTGTGGAAGG
*GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
mouse OSE cells has not been established. The inactivation 
of  brca1 induced developmental delay and resulted in 
embryonic lethality in mice [11,14,23]. Furthermore, 
deficiency of brca2 also induced embryonic lethality by 
the retardation of embryonic development [23,33]. To 
overcome these problems, the Cre-loxP system was 
employed to elucidate the roles of brca1 in tumorigenesis 
through the targeted deletion of genes. Using the Cre-loxP 
system, early studies showed that the conditional knockout 
of brca1 induces mammary tumor and also that concurrent 
inactivation of p53 and Rb1 is sufficient for the induction 
of ovarian carcinogenesis in conditional p53 and Rb1 
knockout mice [12,36]. In this study, we investigated the 
role of brca1 or brca2 with p53 in ovarian carcinogenesis 
using the Cre-loxP system in floxed mice.
Materials and Methods
Cell culture
Ovaries were dissected and washed with phosphate- 
buffered saline (PBS; Invitrogen Life Technologies, USA). 
The ovaries were placed in DMEM/F12 medium containing 
Collagenase (100 U/mL) and Dispase II (0.6 U/mL) for 25 
min at 37
oC in a humidified atmosphere. OSE cells were 
cultured in DMEM/F12 (Sigma-Aldrich, USA) supplemented 
with 10% FBS (Hyclone, USA), 100 U/mL penicillin G 
and 100 μg/mL streptomycin (Life Technologies, USA) at 
37
oC in a humidified atmosphere of 5% CO2.
Mice maintenance
Homozygote mouse strains with brca1
loxP/loxP, brca2
loxP/loxP, 
and p53
loxP/loxP were purchased from the Mouse Repository 
of Mouse Models of Human Cancers Consortium program 
(US National Cancer Institute, USA). FVB inbred mice 
(Charles River, USA) were used as a control group. The 
mice were maintained at a constant temperature (23 ± 2
oC), 
relative humidity of 50∼60%, and a 12 h light/dark cycle. 
Standard rodent chow and purified water were available ad 
libitum. All animal procedures were approved and carried 
out in accordance with the Animal Care Committee of the 
University of British Columbia.
Genotyping and DNA preparation
The mice carrying a brca1, brca2, and p53 conditional 
allele were genotyped by PCR (58
oC, 1 min; 72
oC, 1 min; 
94
oC, 1 min; 30 cycles). Total RNA extracts were prepared 
from the mouse cells using TRIZOL Reagent (Invitrogen 
Life Technologies, USA) and reverse transcribed from 2.5 
ng of total RNA using the First-Strand cDNA Synthesis Kit 
(Amersham Pharmacia Biotech, USA). The sense/antisense 
primers for the floxed sequence and the wild-type sequence 
and the predicted sizes of PCR products of brca1, brca2, 
p53, and glyceraldehyde-3-phosphate dehydrogenase are 
described in Table 1.
Adenovirus administration
Mouse strains with wild type, brca1
loxP/loxP, brca2
loxP/loxP, 
and  p53
loxP/loxP were injected with adeno-Cre virus 
(AdCMVCre) and adeno-EGFP (AdCMVEGFP) (University 
of Iowa Gene Transfer Vector Core) as previously 
described [12]. Briefly, the adenovirus was injected using 
a 1 mL syringe with a 30-gauge beveled needle after 0.5∼
2% isofurane anesthesia. Ovaries were individually 
accessed via dorsal incision and the right ovaries were 
injected with AdCMVCre and the left ovaries were 
injected with AdCMVEGFP.
For in vitro infection, 2 × 10
5 OSE cells were incubated 
with 4 × 10
7 AdCMVCre, and AdCMVEGFP (MOI 200, 
respectively) in 500 μL of serum-free medium for 1.5 h at 
37
oC. Then the cells were washed twice with PBS and Conditional knockout of brca1/2 and p53 in ovarian cancer    293
Fig. 1. Genotyping of floxed mice for brca1 and brca2. (A) The
predicted 461-bp (5´ floxed) and 562-bp (3´ floxed) PCR 
products of were observed in brca1
loxP/loxP mice (Lanes 1-6). (B) 
The predicted 376-bp (5´ floxed) and 529-bp (3´ floxed) PCR 
products of brca2 were confirmed in brca2
loxP/loxP mice (Lanes 
1-6). (C) Confirmation of PCR products of homozygous 
p53
loxP/loxP mice (Lanes 3 and 5). Lanes 6 and 7, heterozygous 
p53
loxP/loxP mice. Lane M: Molecular weight marker, Lane W: 
wild-type.
incubated in DMEM/F12 with 10% FBS. Cells isolated 
from brca1
loxP/loxP and brca2
loxP/loxP mice were infected with 
AdCMVCre to conditionally delete brca1 and brca2 genes. 
A multiplicity of infection (MOI) value was calculated as 
the number of infectious viruses divided by the number of 
cells.
Proliferation assay
The proliferation assay was performed using [
3H]- 
thymidine incorporation assay as previously described [8]. 
Briefly, cells were placed in 24-well plates with 0.5 mL 
DMEM/F12 with 10% FBS. The cells were infected with 
the adenovirus as described above. Following incubation 
for 2 days, 1 μCi [
3H]-thymidine (0.5 Ci/mmol; Amersham 
Pharmacia Biotech, USA) was added. The cells were 
incubated for 6 h and precipitated with 0.5 mL 10% 
trichloroacetic acid for 20 min at 4
oC. The precipitate was 
washed in methanol twice and solubilized in 0.5 mL 0.1 N 
sodium hydroxide. The radioactivity was measured in the 
Tri-Carb Liquid Scintillation Analyzer (Model 2100TR; 
Packard Instrument, USA).
Histopathological analysis
Brca1, brca2, brca1/2, and brca2/p53 floxed mice were 
injected intrabursally with AdCMVCre and AdCMVEGFP 
into the right and left ovaries, respectively. brca1
loxP/loxP, 
brca2
loxP/loxP, or p53
loxP/loxP mice infected with AdCMVCre 
and AdCMVEGFP adenovirus were sacrificed by carbon 
dioxide inhalation according to the standard protocol. 
Ovaries were removed and fixed in 10% formalin, and 
paraffin sections were prepared for microscopic evaluation. 
Serial sections were prepared for hematoxylin and eosin 
staining, and histopathological examination then performed 
under a light microscope.
Statistical analysis
Statistical analysis was performed by one-way ANOVA 
followed by Tukey’s multiple comparison test. p ＜ 0.05 
was considered statistically significant. The results of in 
vitro proliferation assays are presented as the mean ± SD 
following three independent experiments.
Results
Detection of the insertion of loxP sites in brca1 and 
brca2
The insertions of loxP sites in mice carrying a brca1, 
brca2, and p53 conditional allele were confirmed by 
RT-PCR. As demonstrated in Fig. 1A, predicted PCR 
products of 5´ floxed brca1 and 3´ floxed brca1 were 
obtained at 461 and 562-bp, respectively, and 5´ and 3´ 
floxed  brca2 PCR products were observed at 376 and 
529-bp, respectively (Fig. 1B). PCR products from the 
wild type of brca1 and brca2 mice were obtained with the 
same primer sequences of brca1 and brca2. The mice 
bearing floxed p53 gene as confirmed by RT-PCR were 
used for further experiments (Fig. 1C. Lanes 3 and 5).
Determination of MOI to delete the loxP sites of 
brca1 and brca2 following AdCMVCre infection
Cre-loxP recombination was performed to inactivate 
brca1 and brca2 genes. For experiments, 3 × 10
5 cells were 
seeded in 0.5 mL of serum-free medium with serial dilution 
of AdCMVCre. After 1.5 h incubation at 37
oC, the cells 
were washed twice with PBS and covered with DMEM/F12 
containing 10% FBS. Infection of AdCMVCre at MOI 20
∼400 determined by the formula resulted in a decrease of 
brca1 and brca2 expression (Fig. 2A), indicating that 
AdCMVCre administration activated the loxP sequence, 294    Ki-Yon Kim et al.
Fig. 2. Evaluation of multiplicity of infection (MOI) by 
adeno-Cre virus (AdCMVCre) infection for deleting the genes in
ovarian surface epithelium. (A) The expression of brca1 and 
brca2 following treatment with serial dilutions of AdCMVCre. 
Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used to confirm the same amount of loading. (B) Schematic
explanation of Cre-loxP recombination. 
Fig. 3. Effect of inactivation of brca1, brca2, and p53 on ovarian 
surface epithelium (OSE) cell proliferation. OSE cells from 
diverse genotypes were infected with AdCMVCre at MOI 200 
for 1.5 h. Then, cell proliferation was measured by thymidine 
incorporation assay in the OSE cells with brca1
loxP/loxP, 
brca1/2
loxP/loxP, brca2/p53
loxP/loxP and p53
loxP/loxP after infection. 
Adeno-EGFP (AdCMVEGFP) was used as a control. 
Proliferation levels are expressed as a relative fold change. 
Values are the mean ± SD. *p  ＜ 0.05  vs. AdCMVEGFP 
infection.
which successfully excised the brca1 and brca2 genes as 
described in a schematic diagram (Fig. 2B).
Effect of the inactivation of brca1, brca2, and p53 
and on the proliferation of OSE
OSE cells were obtained from brca1
loxP/loxP, p53
loxP/loxP, 
brca1/2
loxP/loxP, and brca2/p53
loxP/loxP mice and infected 
with AdCMVCre at MOI 200 to investigate whether the 
inactivation of brca1, brca2, and p53 affected the 
proliferation of mouse OSE cells. Data from the infection 
group of AdCMVCre were compared to those of the 
vehicle group or the AdCMVEGFP infected group. 
Infection with AdCMVCre in OSE cells resulted in a 
significant increase of proliferation in brca1
loxP/loxP and 
brca2/p53
loxP/loxP groups (Fig. 3), but no difference was 
observed in brca1/brca2 floxed OSE cells (Fig. 3). 
Although the infection of p53
loxP/loxP cells with AdCMVCre 
seemed to increase proliferation of OSE, the increase was 
not significant (Fig. 3).
Effect  of  the  inactivation  of  brca1  and  brca2 o n  
ovarian carcinogenesis 
To evaluate the effect of the deletion of brca1 and brca2 
genes, wild type, brca1
loxP/loxP and brca2
loxP/loxP mice were 
injected with AdCMVCre intrabursally. Following 3 
months of AdCMVCre infection, ovaries were collected 
and examined under a light microscope following staining. 
No morphological changes were observed in the OSE cells 
of brca1 and brca2 floxed mice (data not shown).
Since the effect of concurrent inactivation of brca1 and 
brca2 in ovarian carcinogenesis is not known, double 
knockout mice of these genes were obtained by cross 
breeding. There were no observable differences between 
AdCMVCre and AdCMVEGFP infected groups. In 
addition, no morphological changes were observed in 
brca2/p53
loxP/loxP mice following AdCMVCre administration 
(data not shown).
Discussion
The carriers of brca1 and brca2 mutations have increased 
susceptibility to breast, prostate, and ovarian cancer 
[13,35]. The unique signatures of gene expression profiling 
of brca1 and brca2 have been revealed in hereditary and 
sporadic ovarian cancers [16]. In addition, a significantly 
higher proportion of advanced serous adenocarcinoma in 
ovaries has been observed in the cases of brca1 and brca2 
mutations [31], indicating that the loss of function of these 
genes leads to the outgrowth of ovarian cells. Somatic 
mutations also seem to be involved in ovarian cancer 
development [6,19]. The germline mutations of brca1 and 
brca2 genes in ovarian carcinomas demonstrate a higher 
growth percentage than sporadic cancers do [20,22]. It has 
been reported that brca1 dysfunction is often involved in 
simultaneous brca2 dysfunction in ovarian cancers [18]. 
Although many studies have been performed to elucidate 
the precise role of brca1 and brca2 on ovarian carcinogenesis, 
the studies have struggled to define the exact contribution 
because the knockout of these genes in mice induced 
developmental delay and resulted in embryonic lethality Conditional knockout of brca1/2 and p53 in ovarian cancer    295
[11,14,23,33].
Previous study has shown that when using a conditional 
knockout method, the Cre-loxP system, mutation of brca1 
resulted in mammary tumor formation in the mouse [36]. 
Also, a single intrabursal administration of recombinant 
Cre-expressing adenovirus in double-floxed mice of p53 
and  Rb1 was sufficient for reproducible induction of 
ovarian epithelial carcinogenesis [12]. In this study, we 
investigated whether the concurrent mutation of brca1, 
brca2, and p53 genes is involved in ovarian carcinogenesis. 
Following the confirmation of genomic phenotype of 
floxed brca1, brca2 and p53 in brca1
loxP/loxP, brca2
loxP/loxP 
and  p53
loxP/loxP mice, double homozygous mice of 
brca1/2
loxP/loxP or brca2/p53
loxP/loxP were obtained by cross 
breeding of the single-floxed mice with brca1
loxP/loxP, 
brca2
loxP/loxP, and p53
loxP/loxP mice. We confirmed the loss of 
copies of brca1/2 and brca2/p53 in brca1/2
loxP/loxP or 
brca2/p53
loxP/lox mice by genotyping using PCR. To 
explore the function of brca1, brca2, and p53 in OSE in 
vivo, AdCMVCre was injected intrabursally to induce 
Cre-loxP recombination to delete the exons of brca1 and 
brca2. We examined tumor formation after 3 months of 
AdCMVCre infection. No morphological changes were 
observed in AdCMVCre injected ovaries. A previous 
report has shown that the inactivation of brca1 is sufficient 
for preneoplastic changes such as hyperplasia and inclusion 
cysts following adeno-viral Cre infection but no tumor 
formation was observed [9]. There is also controversy over 
the issue of the effect of inactivation of brca1 on the 
capacity of proliferation of OSE cells [3,9,29]. Discrepancies 
might be due to the different viral constructs or the period 
of infection. In addition, no susceptibility to mammary 
tumors was observed in heterozygous brca1 mutant mice 
[37], suggesting that the existence of the normal functioning 
brca1 gene is possible.
P53 is well known to be absent or mutated in several 
cancer types and the dysfunction of p53 is commonly 
related to ovarian cancer, particularly with germline brca1 
muation [21,27]. brca1/2 are known to have similar 
phenotypic consequences of disruptions [34]. Since the 
precise nature of brca1/2 and p53 interaction remains to be 
defined, we evaluated the effect of the mutation of these 
genes on OSE proliferation. OSE cells obtained from the 
ovaries of conditional knockout mice were infected with 
AdCMVCre to delete the exons of brca1, brca2, and p53 in 
vitro. Infection with AdCMVCre in brca1
loxP/loxP, 
brca2/p53
loxP/loxP OSE cells resulted in an increase of cell 
proliferation, but no proliferative increase was found in the 
AdCMVCre infected brca1/2
loxP/loxP group and p53
loxP/loxP 
group. In addition, no morphological changes were 
observed in brca2/p53
loxP/loxP mice following AdCMVCre 
administration. However, it has been reported that the 
individual inactivation of p53 and Rb1 increases OSE 
proliferation in vivo and the concurrent inactivation of 
those genes demonstrates a synergistic effect on cell 
proliferation [12]. These discrepancies may be partially 
due to the experimental methods used to measure the 
proliferative index, since the level of proliferation is 
similar among these results. However, our results are 
consistent with the finding that the concurrent mutation of 
these genes was not necessary in breast cancer development 
[15]. In addition, a previous report showed that brca2 
interacts with p53 gene and inhibits p53’s transcriptional 
activity in cancer cells [25], suggesting that the concurrent 
inactivation of these genes may not be involved in ovarian 
cancer development and that it is more likely that other 
genes may play a role in ovarian carcinogenesis. It is 
possible that a single intrabursal administration of 
AdCMVCre was not sufficient to inactivate these genes 
and induce ovarian cancer in vivo and further studies using 
more frequent administration or long term maintenance 
following AdCMVCre infection are needed before a 
conclusion can be reached.
In conclusion, we demonstrated in this study that the 
proliferation of OSE was significantly increased in mice 
bearing concurrent floxed copies of brca1 and brca2/p53 
in vitro. However, we did not observe direct evidence of the 
involvement of brca1, brca2, and p53 in ovarian 
carcinogenesis. Also, morphological changes including 
tumor formation were not observed in mice having floxed 
copies of concurrent brca1/brca2 or p53 following an 
intrabursal administration of recombinant Cre-expressing 
adenovirus in vivo. Taken together, these results suggest 
that the inactivation of brca1, brca2 or p53 is unlikely to be 
sufficient for the induction of ovarian epithelial carcinogenesis.
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